A Study of Safety and Efficacy of Tildacerfont in Females With Polycystic Ovary Syndrome and Elevated Adrenal Androgens
An investigation of the safety and efficacy of tildacerfont in women with PCOS and elevated adrenal androgens
Polycystic Ovary Syndrome
DRUG: Tildacerfont|DRUG: Placebo
DHEAS level, Change from baseline in DHEAS level, 12 Weeks (assessed at Baseline, Weeks 4, 8, and 12)
Reduction in DHEAS, Proportion of subjects with \>/=30% change from baseline in DHEAS, 12 weeks (assessed at Baseline, Weeks 4, 8 and 12)|Normalization of DHEAS, Proportion of subjects with DHEAS =/\< upper limit of normal for DHEAS, 12 weeks (assessed at Baseline, Weeks 4, 8 and 12)|Number of subjects with TEAE as assessed by CTCAE Version 5, Evaluation of safety of tildacerfont with PCOS as measured by number of subjects with adverse events following dosing by CTCAE Version 5, 12 weeks (assessed at Baseline, Weeks 4, 8 and 12)
This is a phase 2 study to evaluate the efficacy, safety and tolerability of 3 doses of tildacerfont in approximately 39 women with PCOS and elevated adrenal androgens assessed by elevated DHEAS levels. Subjects will be randomized 2:1 (tildacerfont:placebo) at baseline. The study will consist of 3 consecutive 4-week treatment periods at each dose level. Duration of participation is approximately 25 weeks.